Skip to main content
. 2022 Mar 17;36(6):855–865. doi: 10.1111/jdv.18010

Figure 1.

Figure 1

Study design. Study design for (a) UltIMMa‐1 and UltIMMa‐2 post hoc analysis, full study design included a placebo arm 19 and (b) LIMMitless; OLE, open‐label extension; RCT, randomised controlled trial; RZB, risankizumab; UST, ustekinumab. aPatients weighing ≤100 kg received 45 mg UST, while patients weighing >100 kg received 90 mg UST, per label instructions.